Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta (PI3K p110beta), encoded by the PIK3CB gene, is a class IA phosphoinositide 3-kinase catalytic isoform that plays a critical role in cellular signaling, growth, survival, and metabolism. Unlike other class IA isoforms like p110alpha, which are primarily activated by receptor tyrosine kinases, p110beta is uniquely activated by both receptor tyrosine kinases and G-protein coupled receptors (GPCRs). It is also highly involved in platelet activation and aggregation, making it a key player in thrombosis.
In oncology, PI3K p110beta has emerged as a major therapeutic target, particularly in PTEN-deficient cancers (such as prostate, breast, and endometrial cancers), which exhibit a unique dependency on p110beta signaling rather than p110alpha. Therapeutic strategies targeting this molecule involve selective small-molecule inhibitors, such as GSK2636771 and AZD8186, which bind to the ATP-binding pocket of the enzyme to block downstream AKT pathway activation. However, clinical development of these inhibitors faces challenges, including safety concerns like hyperglycemia, gastrointestinal toxicities, and potential bleeding risks due to its physiological role in platelets.
Inhibition of the catalytic activity of the p110beta subunit of Class IA phosphoinositide 3-kinase (PI3K), preventing the phosphorylation of phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 3,4,5-trisphosphate (PIP3). This blocks the recruitment and activation of downstream effectors such as AKT and PDK1, thereby inhibiting the PI3K/AKT/mTOR signaling pathway, which leads to decreased cell proliferation, survival, and platelet aggregation.
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta (PIK3CB).